Romania

Show information for:

Information and guides

BackSavedSign in

Support / Info

Clinical trials for pancreatic cancer in Romania

Which studies are listed as recruiting, where the centres are, and how to contact the team. Record source: ClinicalTrials.gov.

← All cancer types

How to read this list

Each card is a study listed as recruiting with a recruiting centre in Romania. Open the sections in the card to see the participant overview, study groups, calendar and all published local centres and contacts. The study team confirms eligibility and availability; the original registry record remains available for the complete protocol information.

Trials recruiting now

Every title below has been rewritten in plain language by our editorial team, with the original underneath.

Trials testing a treatment · one study

Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.

NCT07562152Phase 3Listed as recruiting

Metastatic pancreatic cancer, first line: atebimetinib added to gemcitabine and nab-paclitaxel

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Minimum age: 18 years

Centres in: Galați · Suceava

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07562152. This contact may be in another country; ask which language you can use.

Immuneering Study Team

860-321-1302 (dialling format unconfirmed)

clinicaltrials@immuneering.com

Source: study registry

Galați

Suceava

Who can take part

Metastatic pancreatic cancer, first line: atebimetinib added to gemcitabine and nab-paclitaxel

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment naive as follows: * First-line PDAC participants will have received no previous systemic anti-cancer therapy * Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria * Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values Exclusion Criteria: * Inability to swallow oral medications * Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma * Participants with only locally advanced disease * Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Atebimetinib · mGnP

  • Group 2 · Active treatment comparison

    GnP

Start of the whole study
5 June 2026
Completion of the whole study
February 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Updated in the registry: 6 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Observational studies · 2 studies

You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.

NCT06867172Listed as recruiting

Observational study: how often fat build-up in the pancreas occurs alongside pancreatic cysts and cancer

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.

Minimum age: 18 years

Centres in: București

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06867172. This contact may be in another country; ask which language you can use.

Source: study registry

București

Who can take part

Observational study: how often fat build-up in the pancreas occurs alongside pancreatic cysts and cancer

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Age 18 or older * Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam). Exclusion Criteria: * No evidence of written informed consent * Patients with contraindications for endoscopy due to comorbidities * Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary) * Acute pancreatitis at baseline imaging * Pancreatic surgery at baseline imaging in our department * Splenectomy * Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women

What taking part involves

The record does not specify how participants are assigned to groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Group described in the registry

    computerized tomography · Endosonography (EUS)

  • Group 2 · Group described in the registry

    Not specified in the record consulted

  • Group 3 · Group described in the registry

    Not specified in the record consulted

Start of the whole study
1 January 2019
Completion of the whole study
30 June 2025 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

Updated in the registry: 10 March 2025

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07875582Listed as recruiting

Observational study: blood biomarkers for pancreatic cancer diagnosis

The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older. The study will investigate whether these biomarkers can help distinguish pancreatic cancer from chronic pancreatitis and mucinous pancreatic lesions, including intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). The main questions it aims to answer are: Can blood-based protein biomarkers accurately identify patients with PDAC and distinguish them from patients with chronic pancreatitis or mucinous pancreatic lesions? Does combining protein biomarkers with CA 19-9 improve diagnostic accuracy compared with using individual biomarkers alone? Are protein biomarker levels associated with tumor stage, tumor size, or the presence of metastases in patients with PDAC? Researchers will compare blood levels of protein biomarkers across four groups of patients: those with PDAC, chronic pancreatitis, IPMNs, and MCNs. The biomarkers will include GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A. Participants will: Provide informed consent before enrollment. Provide an additional blood sample for protein biomarker measurement, collected alongside routine blood tests and before any oncological or interventional treatment. Have relevant clinical information, medical history, laboratory results, and imaging findings collected for analysis.

Minimum age: 18 years

Centres in: Iași

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07875582. This contact may be in another country; ask which language you can use.

Roxana Grigorovici, medical doctor, PhD student

+40 752 082 830

grigorovici.roxana@d.umfiasi.ro

Catalin V Sfarti, medical doctor, professor

Source: study registry

Iași

Who can take part

Observational study: blood biomarkers for pancreatic cancer diagnosis

The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older. The study will investigate whether these biomarkers can help distinguish pancreatic cancer from chronic pancreatitis and mucinous pancreatic lesions, including intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). The main questions it aims to answer are: Can blood-based protein biomarkers accurately identify patients with PDAC and distinguish them from patients with chronic pancreatitis or mucinous pancreatic lesions? Does combining protein biomarkers with CA 19-9 improve diagnostic accuracy compared with using individual biomarkers alone? Are protein biomarker levels associated with tumor stage, tumor size, or the presence of metastases in patients with PDAC? Researchers will compare blood levels of protein biomarkers across four groups of patients: those with PDAC, chronic pancreatitis, IPMNs, and MCNs. The biomarkers will include GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A. Participants will: Provide informed consent before enrollment. Provide an additional blood sample for protein biomarker measurement, collected alongside routine blood tests and before any oncological or interventional treatment. Have relevant clinical information, medical history, laboratory results, and imaging findings collected for analysis.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion criteria: * Adults aged 18 years or older * Diagnosis of pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis, intraductal papillary mucinous neoplasm (IPMN), or mucinous cystic neoplasm (MCN) * Histopathological confirmation mandatory for PDAC and optional for benign pancreatic conditions * Diagnosis of benign pancreatic conditions confirmed by imaging criteria and/or a minimum clinical follow-up of 12 months * Written informed consent Exclusion criteria: * Less than 3 months since resolution of the most recent episode of acute pancreatitis * Other active malignancies * Severe systemic inflammatory diseases * Oncological treatment initiated before blood sample collection, including chemotherapy or surgical resection * Refusal to participate

What taking part involves

The record does not specify how participants are assigned to groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Group described in the registry

    Blood-Based Protein Biomarker Assessment

  • Group 2 · Group described in the registry

    Blood-Based Protein Biomarker Assessment

  • Group 3 · Group described in the registry

    Blood-Based Protein Biomarker Assessment

  • Group 4 · Group described in the registry

    Blood-Based Protein Biomarker Assessment

Start of the whole study
8 October 2026
Completion of the whole study
December 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma

Updated in the registry: 19 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 19 Nov 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

View the records in the official registries.

Where the data on this page comes from

The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting that also have at least one site in Romania marked as recruiting. We show cities, centre names and contacts when published. General contacts added from the OncoDots directory are labelled separately. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.